Analysts believe that Gilead's new PrEP drug Yeztugo could reach peak sales of $4.5 billion. Not if GSK has anything to say ...

The Handmaid’s Tale has introduced its fair share of unsettling figures over the years, but none have shaken things up quite ...

As Gilead Sciences gets underway with the key launch of its twice-yearly pre-exposure prophylaxis (PrEP) HIV med, the company ...

(Reuters) -Shares of Gilead rose nearly 3% after the U.S. Supreme Court on Friday preserved a key element of the Obamacare ...

Gilead Sciences has blamed the low rate of respiratory syncytial virus (RSV) infections last season for ending two midstage ...

Gilead Sciences, Inc. (NASDAQ: GILD) and Kymera Therapeutics, Inc. (NASDAQ: KYMR), today announced that they have entered ...

Under terms of the deal, Kymera will lead early research on novel oral CDK2 degraders for solid tumors, with Gilead assuming ...

Kymera Therapeutics sweetened news of a setback Wednesday, revealing that Sanofi is pulling back from its lead IRAK4 degrader ...

Before Gilead’s rise, the world in The Handmaid’s Tale was already falling apart. Food shortage, political unrest, environmental disasters — it was all there, bubbling just under the surface.

The website you are visiting is protected and accelerated by Imperva. Your computer may have been infected by malware and ...

Shares of Gilead Sciences Inc. GILD rose 1.60% to $107.62 Thursday, on what proved to be an all-around great trading session ...

By Mariam Sunny and Mrinalika Roy (Reuters) -Shares of Gilead rose 3% after the U.S. Supreme Court on Friday upheld a federal ...